Market Spotlight: Obesity
Market Spotlight: Obesity
$1,318.00
This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2020, there were approximately 686.0 million prevalent cases of obesity in adults (20+ years) worldwide, and expects that number to increase to 758.5 million prevalent cases by 2029.
- In the same year, Datamonitor Healthcare estimates that there were 125.9 million prevalent cases of obesity in children and adolescents (5–19 years) worldwide, and expects that number to increase to 128.3 million prevalent cases by 2029.
- Prevalence proportions are highest in Northern America and lowest in Asia. The approved drugs in the obesity space target gastric lipase, dopamine, norepinephrine (noradrenaline), dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, opioid receptors, GABA-A receptor, and glucagon-like peptide-1 (GLP-1) receptor. The majority of marketed drugs are administered via the oral route, with two products being available in a subcutaneous formulation.
- The largest proportion of industry-sponsored drugs in active clinical development for obesity are in Phase I, with two drugs in Phase III.
- Therapies in development for obesity focus on a wide variety of targets. These therapies are commonly administered via the subcutaneous or oral routes, with one drug being tested in an intravenous formulation.
- High-impact upcoming events for drugs in the obesity space comprise topline Phase II trial results for PF-06882961 and pemvidutide, topline Phase IIb trial results for Tesomet, topline Phase III trial results for tirzepatide, an expected Japanese supplemental approval decision for Ozempic, and a decentralized EU approval as well as an estimated EU patent expiration for Qsymia.
- The overall likelihood of approval of a Phase I obesity asset is 2.5%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 8.3 years from Phase I to approval, compared to 9.6 years in the overall metabolic space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for obesity have been in the early and midphases of development, with 66% of trials in Phase I–II, and 34% in Phase III–IV.
- The US has a substantial lead in the number of obesity clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the obesity space is dominated by completed trials. Novo Nordisk has the highest number of completed clinical trials for obesity, with 88 trials.
- Novo Nordisk leads industry sponsors with the highest overall number of clinical trials for obesity, followed by AstraZeneca.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Medications
9 Surgery
11 EPIDEMIOLOGY
19 MARKETED DRUGS
22 PIPELINE DRUGS
28 RECENT EVENTS AND ANALYST OPINION
28 Ozempic for Obesity (June 26, 2021)
30 Tirzepatide for Obesity (June 25, 2021)
35 Ozempic for Obesity (February 10, 2021)
36 Tesomet for Obesity (November 23, 2020)
38 AM833 for Obesity (June 18, 2020)
40 Ozempic for Obesity (June 12, 2020)
42 Ozempic for Obesity (June 4, 2020)
44 Ozempic for Obesity (May 13, 2020)
47 KEY UPCOMING EVENTS
48 KEY REGULATORY EVENTS
48 Novo Nordisk’s Wegovy Gets EU Thumbs Up But Launch Will Wait
48 Wegovy Is Novo Nordisk’s GLP-1 Agonist In A New Guise For Obesity
48 Obesity Drug Imcivree Among Eight New Products To Win EMA Nod
49 EMA Recommends Label Extension Of Saxenda For Obesity
49 Five New EU Filings Leave Starting Blocks at EMA
49 EMA Reviews Amfepramone Medicines
49 Review Vouchers: Danyelza, Imcivree Earn; Novo Nordisk Spends
50 Rhythm’s Setmelanotide Loses Fast-Track Status In Europe
51 PROBABILITY OF SUCCESS
52 LICENSING AND ASSET ACQUISITION DEALS
52 RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna
52 D&D Pharmatech Signs Licensing And Development Agreement For DD01 With Shenzhen Pregene In China
52 CinFina Gets Four Early-Stage Obesity Injectables From Janssen
53 AstraZeneca, Regeneron To Jointly Pursue Novel Metabolic Target
53 NIMIUM Therapeutics And Paraza Pharma Sign Obesity Deal
53 Novo Nordisk To Apply Lumen Technology To Obesity R&D
53 Piramal Snaps Up Peptide API Specialist Hemmo
54 Boehringer Ingelheim, Gubra Enter Third Obesity Deal
54 Tonix Obtains U. Of Geneva Oxytocin Technology
54 Senda Teams With Nestle Nutritional Health For Metabolic Conditions
55 CLINICAL TRIAL LANDSCAPE
56 Sponsors by status
57 Sponsors by phase
58 Recent events
60 BIBLIOGRAPHY
61 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of obesity in adults, 2020–29
16 Figure 2: Trends in prevalent cases of obesity in children and adolescents, 2020–29
22 Figure 3: Overview of pipeline drugs for obesity in the US
22 Figure 4: Pipeline drugs for obesity, by company
23 Figure 5: Pipeline drugs for obesity, by drug type
23 Figure 6: Pipeline drugs for obesity, by classification
30 Figure 7: Ozempic for Obesity (June 26, 2021): Phase IIIa – STEP 2 (Overweight/obese diabetics)
35 Figure 8: Tirzepatide for Obesity (June 25, 2021): Phase III – SURPASS-2 (vs. Semaglutide)
36 Figure 9: Ozempic for Obesity (February 10, 2021): Phase IIIa – STEP 1 (Weight Loss)
38 Figure 10: Tesomet for Obesity (November 23, 2020): Phase IIa – Hypothalamic Obesity (Denmark)
40 Figure 11: AM833 for Obesity (June 18, 2020): Phase I – w/Semaglutide
40 Figure 12: AM833 for Obesity (June 18, 2020): Phase II – 4433
42 Figure 13: Ozempic for Obesity (June 12, 2020): Phase IIIa – STEP 2 (Overweight/obese diabetics), Phase IIIa – STEP 3 (Maximizing Weight Loss)
44 Figure 14: Ozempic for Obesity (June 4, 2020): Phase IIIa – STEP 1 (Weight Loss)
46 Figure 15: Ozempic for Obesity (May 13, 2020): Phase IIIa – STEP 4 (Maintained Weight Loss)
47 Figure 16: Key upcoming events in obesity
51 Figure 17: Probability of success in the obesity pipeline
55 Figure 18: Clinical trials in obesity
55 Figure 19: Top 10 drugs for clinical trials in obesity
56 Figure 20: Top 10 companies for clinical trials in obesity
56 Figure 21: Trial locations in obesity
57 Figure 22: Obesity trials status
58 Figure 23: Obesity trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of obesity in adults, 2020–29
14 Table 2: Prevalent cases of morbid obesity in adults, 2020–29
15 Table 3: Prevalent cases of obesity in children and adolescents, 2020–29
17 Table 4: Prevalence proportions of obesity and morbid obesity, 2020
20 Table 5: Marketed drugs for obesity
24 Table 6: Pipeline drugs for obesity in the US
28 Table 7: Ozempic for Obesity (June 26, 2021)
31 Table 8: Tirzepatide for Obesity (June 25, 2021)
35 Table 9: Ozempic for Obesity (February 10, 2021)
37 Table 10: Tesomet for Obesity (November 23, 2020)
39 Table 11: AM833 for Obesity (June 18, 2020)
41 Table 12: Ozempic for Obesity (June 12, 2020)
43 Table 13: Ozempic for Obesity (June 4, 2020)
45 Table 14: Ozempic for Obesity (May 13, 2020)
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Acute Lymphoblastic Leukemia (ALL) 
Sign up to the